Laboratorio Reig Jofre, S.a. · BME:RJF
Laboratorio Reig Jofre — Reig Jofre — FY2024 Earnings Presentation
16 slides from Laboratorio Reig Jofre's earnings presentation, March 2025
Slide 1: Financial Results 2024
FINANCIAL RESULTS 2024 PHARMA SECTOR
Slide 2: Statement
STATEMENT This presentation does not contain confidential material and may include publicly available market information that has not been independently verified by Reig Jofre. This information is given in summary form and does not purport to be complete. The information contained in this presentati
Slide 3: Table of Contents
TABLE OF CONTENTS 2024 Results → Results statement and balance sheet for 2024 → Evolution of RJF shares 3
Slide 4: Results 2024: revenue grew 7% and EBITDA 8%
RESULTS 2024 Reig Jofre’s revenue grew 7% and its EBITDA 8%. Its consolidated profit surpassed 10 million Sed ut perspiciatis → Sales in 2024 closed at 339 million euros, +7% higher than in 2023. Leading this growth is SALES its medical products division – Specialty Pharmacare – rising in the double
Slide 5: Revenue by Business Units
REVENUE BY BUSINESS UNITS SALES 2024 € 338.9 M +7% PHARMACEUTICAL SPECIALTY CONSUMER TECHNOLOGIES PHARMACARE HEALTHCARE Antibiotics Osteoarticular OTC / Energy / Stress and sleep Injectables / Freeze-dried Dermatology / Weight control / Beauty € 151.3 +9% M 45% € 115.3M +10% 34% € 72 .3M +0,1% 21% →
Slide 6: International Developments
INTERNATIONAL SPAIN Sed ut perspiciatis Resto of EUROPE Sed ut perspiciatis Rest Of WORLD DEVELOPMENTS 41% 48% 11% € 140.4 M € 159.9 M € 38.6 M → Markets outside from Spain grew by 13% and represent 59% of total sales. This 0% +16% +3% growth is a combination of direct sales through our own teams an
Slide 7: Table of Contents
TABLE OF CONTENTS → 2024 Results Results statement and balance sheet for 2024 → Evolution of RJF shares 7
Slide 8: Results Statement
→ Sales figures increased by 7% with an associated gross RESULTS STATEMENT margin of 59%, +100 basis point year-on-year. 2024 → The activation of development projects stood at 2.5 million euros. INCOME STATEMENT (thousand euros) 30/09/2023 31/12/2024 V% Turnover 316.088 338.895 7% → Personnel costs
Slide 9: Balance Sheet: Assets and Investments
BALANCE SHEET INVERSTMENT 2024 ASSETS AND INVESTMENTS 31/12/2024 Million euros BALANCE SHEET (thousand euros) 31/12/2023 31/12/2024 Goodwill 27.985 26.809 Biotechnology Other intangible assets 63.070 55.285 Assets Property, plant and equipment 91.625 97.030 6.6 Investments in equity-accounted invest
Slide 10: Balance Sheet: Liabilities and Debt
BALANCE DE SITUACIÓN PASIVOS Y DEUDA 31/12/2024 GROSS FINANCIAL DEBT BALANCE SHEET (thousand euros) 31/12/2023 31/12/2024 TOTAL EQUITY Capital grants 204.254 3.571 213.950 3.620 € 67.3 DEBT LEASES APPLICATION IFRS 16 €9.6 M Provisions 199 225 Milone DEBT WITH CREDIT INSTITUTIONS + Financial liabilit
Slide 11: Table of Contents
TABLE OF CONTENTS → 2024 Results → Results statement and balance sheet for 2024 Evolution of RJF shares 1 1
Slide 12: Evolution of Shares RJF
EVOLUTION OF SHARES RJF YTD DESEMBER 24 MARKET CAPITALIZATION €201 M VOLUME CASH VALUATION RJF (ISIN ES0165359029) €2.49/Share - 31/12/2024 maximum minimum 5.1 M €14.3 M → IBEX SMALL CAP component €2.78/Share €3.20/Share €2.29/Share YTD Titles YTD Weighted average 14/06/2024 19/01/2024 20 k titles €
Slide 13: Save the Date
SAVE THE DATE RESULTS 2024 AND OUTLOOK 2025 MARCH 13, 2025, AT 9:30 AM MADRID STOCK EXCHANGE PALACE Plaza de la Lealtad 1, Madrid LIVE WEBCAST Spanish/ English Available at www.reigjofre.com
Slide 14: Links and Complementary Information
LINKS AND INFORMATION COMPLEMENTARY → RESULTS WEBCAST https://reigjofre.com/es/inversores/webcasts/ → NEWSLETTER RJF https://reigjofre.com/es/inversores/presentaciones/ http://www.reigjofre.com/es/noticias/centro-suscripcion → INVESTORS FINANCIAL AND OTHER RELEVANT INFORMATION https://reigjofre.com/
Slide 15: Alternative performance measures
REIG JOFRE Alternative performance measures Sed ut perspiciatis Management uses certain alternative performance measures in making financial, operating and planning decisions, as well as to evaluate the performance of the Group and its subsidiaries. Management believes that these alternative perform
Slide 16: Thank You
2024 THANK YOU Gran Capità 10 08970 Sant Joan Despí BARCELONA, SPAIN T. +34 93 480 67 10 www.reigjofre.com Investor Relations investors@reigjofre.com